in Rochester, New York. Community-dwelling healthy persons у65 years old and persons 121 years old who had underlying symptomatic cardiopulmonary conditions were prospectively evaluated for RSV infection. Evidence of infection was also sought in persons who were у65 years old or had underlying cardiopulmonary disease and who were hospitalized with acute respiratory symptoms. Sixty-nine RSV infections were identified by culture, reverse-transcription polymerase chain reaction, or serologic testing in the prospective groups, and 61 were identified in the hospitalized group. The presence of underlying chronic pulmonary disease (odds ratio [OR], 3.97), functional disability (OR, 1.67/ integer increase in Instruments of Activities of Daily Living score), and low serum neutralizing antibody titer (OR, 5.89) were each independently associated with increased risk of severe disease, defined as "hospitalization with RSV infection." These data suggest that the induction of neutralizing serum antibody with an RSV vaccine may potentially reduce disease severity in adult populations.
resulted in hospitalization. Identification of risk factors for severe RSV infection is important for the development of RSV vaccines and for targeting the appropriate adult populations. Therefore, we analyzed the influence of clinical variables and neutralizing serum antibody on disease severity, defined as illness requiring hospitalization, in RSV-infected, community-dwelling elderly persons.
SUBJECTS, MATERIALS, AND METHODS

Subjects.
Two groups of independently living adults were recruited and enrolled during the fall of each year (1999 and 2000) . The first group included persons у65 years old who were free of disabling underlying illnesses (identified as the healthy elderly group), some of whom had mild chronic medical conditions, such as diabetes mellitus, hypertension, asymptomatic or stable coronary artery disease, and minimally symptomatic pulmonary disease. The second group consisted of persons у21 years old who had symptomatic congestive heart failure (CHF), defined as a physician's diagnosis or an ejection fraction !35%, or symptomatic pulmonary disease, primarily chronic obstructive pulmonary disease (COPD) (identified as the high-risk group). These 2 populations were selected for study because it was assumed that they would be the most likely to have complicated RSV infections, analogous to what has been shown for influenza virus infection. Subjects recruited during the first year were monitored for 2 winters, whereas subjects recruited during the following year were monitored for 1 winter. Only 1 RSV illness/ subject was analyzed. In addition, all adults hospitalized at Rochester General Hospital with acute respiratory symptoms were evaluated for RSV infection if they were у65 years old or if they had received a diagnosis of underlying CHF or pulmonary disease (hospitalized group). At enrollment, informed consent was obtained, and demographic, medical, and functional performance data were recorded on standardized forms. Functional status was assessed by use of 2 activity scales: a modified version of the Katz Activities of Daily Living (ADL) and the Instruments of Activities of Daily Living (IADL) [9, 10] . The ADL rates 6 basic activities (bathing, dressing, toileting, transfer, continence, and feeding), and the IADL rates 6 more-complex activities (shopping, telephone use, monetary transactions, house or yard work, food preparation, and transportation). Zero points are assigned if completely independent, 1 point is assigned if assistance is required, and 2 points are assigned if completely dependent, with a range from 0-12. Baseline blood samples for antibody determination were obtained from the 2 prospective groups on enrollment during the fall, and acute-phase blood samples were obtained from the hospitalized group at admission to the hospital. The study was approved by the Rochester General Hospital and the University of Rochester Research Subjects Review Boards.
Evaluation of illness. Prospectively enrolled subjects were instructed to notify the study team of all respiratory illnesses or any worsening of baseline cardiopulmonary symptoms during the study period of 15 November 1999-15 April 2001. For the prospectively enrolled groups, illnesses were evaluated by a study nurse during home visits; for the hospitalized group, a study nurse and one of the investigators evaluated the subject within 48 h of admission. At the time of evaluation, a nasopharyngeal swab (NPS) was obtained, was placed in viral transport media, and was transported to the laboratory, on wet ice, for virus identification. Details of the subject's illness, physical examination, and laboratory data were obtained by interviewing patients and by review of medical records. Blood samples for diagnosis of acute RSV infection by serologic testing were obtained during the acute illness evaluation and 4-6 weeks later.
Laboratory methods. Diagnosis of RSV infection was confirmed by culture, serologic testing, or reverse-transcription polymerase chain reaction (RT-PCR), by use of established methods [11, 12] . Virus was isolated from NPS samples on HEp-2 cell monolayers in tubes and was confirmed by indirect immunoflourescence by use of RSV-specific monoclonal antibodies (MAbs; Bartels). An EIA was used to measure serum IgG titers to purified RSV envelope glycoproteins (F, Ga, and Gb), as described elsewhere [11] . RT-PCR was performed on the NPS by use of a single-tube nested reaction using primers derived from the RSV F gene [12] . A diagnosis of RSV infection was defined as a у4-fold increase in EIA titer to any of the RSV antigens, isolation of RSV by culture, or a positive RT-PCR result. In some cases, RSV subgroup was identified by a strain-specific RT-PCR, by use of methods described elsewhere [13] .
Serum RSV neutralizing antibody titers were determined by microneutralization assay using the A2 strain of RSV, as described elsewhere [8] . In brief, 50 pfu of A2 RSV was mixed in 96-well culture plates with replicate dilutions of heat-inactivated serum for 30 min at room temperature. Then 1.5 ϫ 10 4 HEp-2 cells, suspended by treatment with 0.1% ethylenediamine in PBS, were added to the serum-virus mixture. The plates were incubated for 3 days in 5% CO 2 at 35ЊC then were washed and fixed with 75% acetone in PBS. The magnitude of RSV growth was determined by an EIA using a MAb to the RSV F protein, followed by horseradish-peroxidase conjugated goat anti-mouse IgG and substrate. The neutralization titer is defined as the serum dilution that results in a 50% reduction in color development, compared with control wells without serum. For prospective subjects, the serum sample obtained on enrollment was used for analysis; for hospitalized subjects, the acute blood sample obtained on admission was used.
Statistical methods. Differences between means and proportions were evaluated by t test and x 2 test, respectively. Logisticregression analysis was used to assess the conditional associations between hospitalization and each predictor, adjusted for all others. Variables incorporated in the analysis included age, sex, the presence of underlying diseases (pulmonary disease, CHF, coronary artery disease, and diabetes), a functional score (IADL), and serum RSV neutralizing antibody titer. For the analysis, serum neutralizing titers dichotomized at a value of 10 (i.e., !10 and у10 log 2 serum dilution), the nearest integer to the mean and the median. Age was dichotomized at 65 years, following the sampling scheme; IADL was modeled linearly in the logit because this markedly improved the fit of the model (as measured by deviance), compared with dichotomizing IADL. Smoking history, home use of O 2 , and oral steroid use were highly correlated with presence of pulmonary disease and, thus, were not included in the analysis. total of 315 hospitalized persons were evaluated during the first winter, and 310 were evaluated during the second winter. Overall, 130 RSV infections were identified during the 2 winters: 61 in subjects in the hospitalized group, 32 in subjects in the healthy elderly group, and 37 in subjects in the high-risk group (table 1) . The RSV infections were evenly distributed between the 2 winters, for each group, and there was no obvious difference in number or severity of respiratory illnesses between the 2 winters. Two hospitalized subjects had dual RSV and influenza virus infection. Diagnosis of RSV infection was confirmed by culture or RT-PCR in 70% of subjects and by serologic testing alone in the remainder. Strain typing for 53 subjects indicated that group A and B RSV were equally distributed among the hospitalized and nonhospitalized subjects during each of the 2 winters (26 group A and 27 group B). Demographic data for the RSV-infected subjects are shown in table 2. Subjects in the healthy elderly group and the hospitalized group were 5 years older, on average, than those in the high-risk group. The hospitalized group had a higher proportion of women and slightly higher rates of coronary artery disease than the prospective outpatient cohorts. The IADL score and the Katz score, a measure of frailty, were greatest in the hospitalized group. Of the 61 subjects with RSV infections in the hospitalized group, 9 (15%) would have been classified as independently living, healthy elderly persons if they had been evaluated before admission. The remaining 52 subjects (85%) had symptomatic underlying cardiopulmonary conditions (COPD, asthma, and CHF) or a chronic debilitating medical condition, such as malignancy, cerebrovascular disease, or renal failure requiring dialysis. Of the 37 RSV infections in subjects in the high-risk group, 9 (24%) were associated with hospitalization for respiratory illnesses. Five of the hospitalizations were definitely precipitated by RSV infection, and 4 were probably precipitated by RSV infection. The latter 4 hospitalizations were at institutions other than the Rochester General Hospital, and neither acute serum nor NPS samples for diagnosis by culture or RT-PCR were available. In the 4 subjects thus hospitalized, RSV infection was diagnosed by a у4-fold increase in RSV titers between preillness and posthospitalization serum samples. None of the 32 RSV infections in subjects in the healthy elderly group were associated with hospitalization. This rate was statistically different from the rate of definite and probable RSV-associated hospitalizations in the high-risk group (0/32 vs. 9/37; ). P p .002 To identify factors associated with severe disease, multivariate analysis using hospitalization with RSV infection as the outcome variable was performed. The 2 hospitalized subjects with dual RSV and influenza infection and the 4 high-risk subjects in whom RSV infection could not be definitively linked to hospitalization were not included, thus leaving 124 RSV-infected subjects for analysis. Factors that were independently associated with severe disease (i.e., hospitalization) were age !65 years, underlying pulmonary disease (odds ratio [OR], 2.56; ), P p .078 poor functional status by the IADL scale (OR, 1.79/integer increase in IADL score;
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), and the presence of low neu-P p .0008 tralizing antibody titer (OR, 3.59; ) (table 3) . P p .018 The difference in the mean serum neutralizing antibody titer between hospitalized and nonhospitalized subjects was 2-fold (10.1 vs. 11.1 log 2 serum dilution; ), with substantial P p .002 overlap between the 2 groups. However, the mean duration of symptoms before hospitalization and evaluation was ∼7 days, and, thus, acute serum neutralizing titers from the hospitalized group do not accurately reflect true baseline preinfection values, since titers can increase rapidly during an anamnestic response to reinfection with RSV. Therefore, a second analysis was performed after the 19 hospitalized subjects in whom the onset of symptoms was у7 days before admission had been excluded. In this analysis, the same factors associated with severe disease found in the first analysis were also identified as significant (table 4). The OR for the presence of underlying pulmonary disease increased to 3.97 ( ) and remained the same P p .026 for functional disability. The OR for low neutralizing antibody titers increased to 5.89 ( ), and the difference in neu-P p .006 tralizing titer between the hospitalized and nonhospitalized subjects increased to ∼3-fold (9.7 vs. 11.1 log 2 serum dilution; ) (figure 1). When only subjects with underlying P p .0001 high-risk conditions (COPD and CHF) were compared, the neutralizing titers were significantly greater in nonhospitalized NOTE. The 4 subjects from the high-risk group with RSV infections not definitely associated with hospitalization and the 2 subjects with dual RSV and influenza virus infection are not included in the analysis. CI, confidence interval; IADL, Instruments of Activities of Daily Living; OR, odds ratio. subjects than in hospitalized subjects (11.03 vs. 9.96 log 2 serum dilution;
). P p .001
DISCUSSION
The recent recognition of RSV as a cause of serious acute respiratory disease in adult populations has generated interest in the development of vaccines and therapeutic or prophylactic agents for this population [14, 15] . To target those persons most in need, it is important to identify factors placing persons at greatest risk of increased morbidity from RSV infection. Since immunization strategies generally focus on induction of serum antibody, it is also essential to define the relationship between serum neutralizing antibody and the incidence and severity of RSV infection in adults.
Our results indicate that the presence of underlying pulmonary disease, as well as overall functional disability, are significant risk factors for severe illness. The vast majority of subjects with pulmonary conditions in our study had COPD, and this specific factor was also independently associated with hospitalization (data not shown). This is not surprising, as similar conclusions have been drawn about the risk of serious outcome during influenza virus infections [16] . Barker et al. have reported that pneumonia and influenza mortality increased 24-fold in elderly persons with 1 high-risk condition, such as lung disease. RSV is classically associated with wheezing in infants and adults, and, thus, patients with a predisposition to bronchospasm, such as those with COPD, may be particularly vulnerable to severe manifestations of RSV infection [17, 18] . Unlike the presence of influenza infection, the presence of CHF, coronary artery disease, and diabetes mellitus were not associated with a statistically increased risk of hospitalization with RSV infection.
The influence of functional disability, independent of underlying condition, on risk of hospitalization was most notable. The OR increased nearly 2-fold for each integer increase in the IADL score. To place this in perspective, an elderly person who requires some assistance with housework and preparing meals (IADL score p 2) would have a 4-fold increase in risk of hospitalization with RSV infection, and a completely dependent person would have a ∼20-fold increase in risk of hospitalization. Thus, although traditional high-risk conditions-such as diabetes mellitus, CHF, and coronary heart disease-were not independently associated with greater risk of hospitalization in our analysis, the presence of functional disability, regardless of cause, was important. These results suggest that potential vaccine target groups should include not only those with underlying pulmonary disease but also those with functional impairment due to any cause. Notwithstanding this conclusion, it should be noted that 15% of the patients hospitalized with RSV infection would have been classified as independently living, healthy elderly persons if they had been evaluated before admission.
The finding that subjects !65 years old were ∼4 times more likely to be hospitalized than older subjects with RSV infection was unexpected. This finding may be the result of the sampling scheme, since younger subjects were included only if they had significant underlying cardiopulmonary disease. It is possible that lung disease diagnosed at a younger age is more severe than those diagnosed at a more advanced age. Since we did not adjust for disease severity, this may have affected the impact of age on outcome.
Perhaps most importantly, we found that the level of neutralizing antibody was inversely correlated with the risk of hospitalization during acute RSV infection. The ability of serum neutralizing antibody to modify disease severity in high-risk elderly persons is analogous to findings in high-risk infants prophylactically administered RSV-neutralizing monoclonal or polyclonal immunoglobulin preparations [19, 20] . Although the incidence of RSV infection in infants was not diminished, severity, as judged by hospital days and intensive care unit admissions during RSV infection, was reduced. The absolute difference in mean neutralizing antibody titer in hospitalized high-risk adults was only 2-3-fold lower than the titers found in those not requiring hospitalization, and there was significant overlap in antibody titers between the 2 groups. Thus, we could not define a level that provides absolute protection in elderly or high-risk adults. This is consistent with our previous report in which risk of RSV infection was inversely correlated with serum neutralizing antibody levels in frail elderly persons attending adult day care centers [8] . In that study, there was also a large overlap in titers between infected and uninfected control subjects. Despite an incomplete understanding of immunity to RSV infection, the results reported here provide encouragement that induction of higher levels of serum neutralizing antibody in high-risk adults could reduce disease severity and hospitalization during RSV infection.
It is possible that the use of neutralizing titers to the laboratory-adapted RSV A2 strain may not be optimal, given that approximately half of the infections were due to group B RSV strains. Logically, the ideal analysis would have used RSV group-specific neutralization titers that corresponded to the infecting RSV group for each subject. Unfortunately, the RSV group could not be determined in the one-third of subjects for whom the diagnosis of RSV infection was made by serologic testing alone. However, we found that, in 37 subjects from the prospective groups, the correlation coefficient between RSV A2 neutralizing titers and RSV B1 titers was 0.84, which suggests that our RSV A2 neutralization assay is a reasonable surrogate for neutralizing capacity of all RSV strains (authors' unpublished data).
In summary, we have found that, in elderly adults, the presence of underlying pulmonary disease, poor functional performance status, and low serum neutralizing antibody titers are risk factors for hospitalization with RSV infection. The results of the present study suggest that RSV vaccines that stimulate humoral immunity may play a role in reducing disease burden in adults with significant functional impairment or lung disease. Larger studies will be needed to define the total burden of disease in healthy elderly populations.
